US · Healthcare · Drug Manufacturers - Specialty & Generic
Analysts rate Haleon plc a buy (3 buy, 2 hold, 0 sell out of 5) with an average price target of $10.40.
CONFIDENT Q2 organic growth 3.1%, beating Q1's 2.2%. North America gaining momentum via shelf resets and innovation. Margin expansion 120bps from supply-chain efficiency. FY26 guidance 3–5% reaffirmed. Cold & flu recovery and emerging market strength expected H2. Q2 FY26 Emerging markets expected high single digits H2. North America 3–4% target mid-term. Europe 2–3% expected H2 despite tougher backdrop. Middle East facing market declines (Dubai, Pakistan) with recovery planned via activation. Analysts pressed on respiratory headwinds, Asia-Pac pricing trade-offs, and oral care durability vs. competitors. Management reaffirmed cyclical cold-flu recovery, defended margin quality (efficiency-driven), and noted LatAm leadership change enabling pricing discipline; no systemic infrastructure gaps acknowledged. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| Dodge & Cox | 1.70% |
| FMR Inc | 1.38% |
| ClearBridge Advisors, LLC | 0.37% |
| Morgan Stanley - Brokerage Accounts | 0.22% |
| Harris Associates L.P. | 0.19% |
| Harding Loevner L.P. | 0.18% |
| Nuveen, LLC | 0.17% |
| Arrowstreet Capital Limited Partnership | 0.16% |
| Document | Date |
|---|---|
| Transactions in own shares (6-K) · Q4 2026 HEADLINE NUMBERS • Haleon purchased 4,492,636 ordinary shares under its share buyback programme announced on 29 October 2026. • The shares will be h | 2026-11-02 |
| Commencement of gbp 500m share buyback programme (6-K) · Q4 2026 HEADLINE NUMBERS • Haleon has started a share buyback programme worth up to £500 million. • The programme began on 29 October 2026 and must end no l | 2026-10-29 |
| Haleon 2026 q3 trading statement (6-K) · Q4 2026 HEADLINE NUMBERS • This Form 6-K announces that Haleon plc’s Q3 2026 trading statement for the year ending 31 December 2026 was released on 29 Octobe | 2026-10-29 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • This is an indenture dated August 21, 2026 for potential future debt issuance by Haleon. • The document does not disclose a speci | 2026-08-21 |
| Cash tender offer - pricing, expiration and result (6-K) · Q3 2026 HEADLINE NUMBERS • Haleon announced the pricing, expiration and results of a cash tender offer for all outstanding 2027 notes issued by its wholly ow | 2026-08-19 |
| Transactions in own shares & buyback update (6-K) · Q3 2026 HEADLINE NUMBERS • Haleon purchased 1,569,800 ordinary shares on 17–18 August 2026 for cancellation under its buyback programme. • The company has c | 2026-08-19 |
| Transactions in own shares (6-K) · Q3 2026 HEADLINE NUMBERS • Haleon purchased 10,995,213 ordinary shares for cancellation under its share buyback programme announced on 12 March 2026. • Purc | 2026-08-17 |
| Launch & price: $2bn three-tranche bond offering (6-K) · Q3 2026 HEADLINE NUMBERS • Haleon launched and priced a $2 billion, three-tranche U.S.-dollar bond offering on 12 August 2026; settlement is scheduled for 21 | 2026-08-13 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.06 / share ex-date Aug 14, 2026 · pay Sep 17, 2026 | 2026-08-14 |
| Dividend | $0.13 / share ex-date Apr 10, 2026 · pay May 14, 2026 | 2026-04-10 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Haleon plc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.